PMC:7534795 / 41098-41482 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T192","span":{"begin":19,"end":27},"obj":"Body_part"},{"id":"T193","span":{"begin":170,"end":179},"obj":"Body_part"}],"attributes":[{"id":"A192","pred":"fma_id","subj":"T192","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A193","pred":"fma_id","subj":"T193","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T273","span":{"begin":85,"end":90},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T274","span":{"begin":328,"end":329},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T316","span":{"begin":85,"end":90},"obj":"Chemical"},{"id":"T317","span":{"begin":117,"end":128},"obj":"Chemical"}],"attributes":[{"id":"A316","pred":"chebi_id","subj":"T316","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_53276"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T307","span":{"begin":0,"end":16},"obj":"Sentence"},{"id":"T308","span":{"begin":17,"end":103},"obj":"Sentence"},{"id":"T309","span":{"begin":104,"end":179},"obj":"Sentence"},{"id":"T310","span":{"begin":180,"end":203},"obj":"Sentence"},{"id":"T311","span":{"begin":204,"end":229},"obj":"Sentence"},{"id":"T312","span":{"begin":230,"end":384},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T153","span":{"begin":19,"end":33},"obj":"Phenotype"},{"id":"T154","span":{"begin":59,"end":64},"obj":"Phenotype"},{"id":"T155","span":{"begin":284,"end":289},"obj":"Phenotype"}],"attributes":[{"id":"A153","pred":"hp_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A154","pred":"hp_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/HP_0031273"},{"id":"A155","pred":"hp_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}

{"project":"2_test","denotations":[{"id":"33031856-32586396-84038884","span":{"begin":379,"end":383},"obj":"32586396"}],"text":"• CytoResc Trial\n• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study\n• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines\n• N = 40–50 ‘CytoSorb’\n• N = 40–50 standard care\n• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)"}